All articles
Publications
Clinical trials
Drugs
Diseases

Catalogue

Loading Lonevi

Please wait while we prepare your medical assistant...

Your health records in one place

Products

Health Score test
For partners
Technical specification
Articles
Science
Publications
Clinical trials
Drugs
Diseases
Manifesto
Shop
Shop catalogue

Legal

Terms of Service
Privacy Policy
Medical Data Consent
Cookie Policy
Ethics policy

Connect

Telegram channel
Support: questions about the service

Language

Lonevi is an informational service. We are not a medical organization, do not provide diagnoses or prescribe treatment. Any information in the service is educational. For health concerns, consult a licensed physician.

Do not use the service for acute symptoms — call your local emergency number.

© 2026 DreamLight LLP. All rights reserved.Part of VARDIX Group

Developed by DreamLight Labs

← All of Science

Drugs

Substances by international nonproprietary name (INN) and ATC code, with their current status.

Evidence

Any
Very low
Low
Moderate
High

Closeness to humans

Any
Cells in vitro
Animals
Early human trials
Proven efficacy in humans

Axis

Any
Genomic instability
Telomere attrition
Epigenetic alterations
Loss of proteostasis
Disabled macroautophagy
Deregulated nutrient sensing
Mitochondrial dysfunction
Cellular senescence
Stem cell exhaustion
Altered intercellular communication
Chronic inflammation
Dysbiosis

Order

Newest
By name
Strongest evidence
Closest to humans

10 cards

DrugIn clinical trials
Trontinemab
trontinemab
Международная Phase 3 PrevenTRON — предотвращение Alzheimer до симптомов.
No news yet
Drug
Rosuvastatin
rosuvastatin
ASTEROID, SATURN; сравнение с atorvastatin.
No news yet
Drug
Ezetimibe
ezetimibe
Add-on after statin; PRECISE-IVUS, IMPROVE-IT.
No news yet
Drug
Bempedoic acid
bempedoic acid
CLEAR Harmony, CLEAR Outcomes.
No news yet
DrugIn clinical trials
Pelacarsen
pelacarsen
Novartis/Ionis; Lp(a)HORIZON Phase 3 — исход 04.09.2026 сообщён как miss.
No news yet
Drug
Obicetrapib
obicetrapib
BROADWAY Phase 3: выраженное снижение LDL-C на фоне липидснижающей терапии.
No news yet
Drug
Inclisiran
inclisiran
Hard-outcome эффект формально не доказан; ORION-4, VICTORION-2 PREVENT, VICTORION-PLAQUE.
No news yet
Drug
Finerenone
finerenone
Нестероидный антагонист минералокортикоидных рецепторов; FINEARTS-HF, FIDELIO-DKD, FIGARO-DKD.
No news yet
DrugApproved
Levacetylleucine (AQNEURSA)
levacetylleucine
FDA одобрила 18.09.2026 для ataxia при ataxia-telangiectasia; второе показание после Niemann-Pick C (2024).
No news yet
DrugApproved
Enlicitide (LIPFENDRA)
enlicitide
FDA 17.07.2026: первый пероральный PCSK9-ингибитор для снижения LDL-C у взрослых с гиперхолестеринемией, включая HeFH.
No news yet